Journal article
Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
- Abstract:
- Dexamethasone can reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment were to be rolled out in the UK and globally, as well as the cost-effectiveness of implementing this intervention. Assuming SARS-CoV-2 exposure levels of 5% to 15%, we estimate that, for the UK, approximately 12,000 (4,250 - 27,000) lives could be saved between July and December 2020. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 (240,000 - 1,400,000) lives saved globally over the same time period. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, for example in low- and middle-income countries.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 786.1KB, Terms of use)
-
(Preview, Version of record, 337.8KB, Terms of use)
-
- Publisher copy:
- 10.1038/s41467-021-21134-2
Authors
- Publisher:
- Springer Science
- Journal:
- Nature Communications More from this journal
- Volume:
- 12
- Issue:
- 1
- Article number:
- 915
- Place of publication:
- England
- Publication date:
- 2021-02-10
- Acceptance date:
- 2021-01-04
- DOI:
- EISSN:
-
2041-1723
- Language:
-
English
- Keywords:
- Pubs id:
-
1161131
- Local pid:
-
pubs:1161131
- Deposit date:
-
2021-03-03
Terms of use
- Copyright holder:
- Águas et al.
- Copyright date:
- 2021
- Rights statement:
- ©2021 The Authors. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- Notes:
- An author correction for this article is available online at: https://doi.org/10.1038/s41467-021-22038-x
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record